CLDX
Celldex Therapeutics, Inc.
There isn't enough reported data to score CLDX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CLDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
CLDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLDX PE Valuation
CLDX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CLDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CLDX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CLDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.65 | -$0.39 |
| Q2 2023 | -$2.41 | -$0.27 |
| Q1 2023 | -$2.53 | -$0.82 |
| Q4 2022 | -$2.40 | -$0.76 |
| Q3 2022 | -$2.26 | -$0.50 |
| Q2 2022 | -$2.14 | -$0.47 |
| Q1 2022 | -$1.71 | +$0.12 |
| Q4 2021 | -$1.64 | +$0.50 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 263% for CLDX versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CLDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $22K | -97% |
| Q1 2026 | $15K | -98% |
| Q4 2025 | $121K | -90% |
| Q2 2025 | $730K | -71% |
| Q1 2025 | $695K | +346% |
| Q4 2024 | $1.2M | -72% |
| Q3 2024 | $3.2M | +110% |
| Q2 2024 | $2.5M | +832% |
CLDX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -366468% | -357721 points |
| Q1 2026 | -562900% | -553873 points |
| Q4 2025 | -72027% | -67259 points |
| Q2 2025 | -8748% | -6893 points |
| Q1 2025 | -9027% | +17004 points |
| Q4 2024 | -4768% | -3615 points |
| Q3 2024 | -1634% | +1085 points |
| Q2 2024 | -1854% | +10536 points |
CLDX's operating margin was −366468% last quarter, down 357441 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CLDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CLDX on profitability, with a higher operating margin.
CLDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$66.7M | -$17.6M |
| Q2 2026 | -$60.6M | -$15.9M |
| Q1 2026 | -$67.2M | -$12.6M |
| Q4 2025 | -$65.2M | -$32M |
| Q3 2025 | -$49.1M | +$6.8M |
| Q2 2025 | -$44.7M | -$15.1M |
| Q1 2025 | -$54.6M | -$13.7M |
| Q4 2024 | -$33.2M | -$33K |
CLDX has burned cash in almost every quarter: −$260M over the past year, against −$182M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CLDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +691K shares |
| 1 year | +67% | +31.6M shares |
| 3 years | +351% | +61.1M shares |
CLDX has 79M diluted shares, up 67% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CLDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CLDX Net Leverage
CLDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CLDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 11.5 | Oversold |
CLDX's weekly RSI is 41 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CLDX PE vs Healthcare Sector
CLDX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.7 | 4.1% below |
| 20 week MA | $35.1 | 19% below |
| 50 week MA | $31.6 | 9.7% below |
| 100 week MA | $27.1 | 5.2% above |
| 200 week MA | $31.2 | 8.4% below |
CLDX's trend is mixed: it's above one of its five weekly moving averages, and 8.4% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CLDX on trend strength, trading above more of its moving averages.
CLDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.22 | $17.5 | +687% |
| 2021 | $17.5 | $42.0 | +140% |
| 2022 | $42.0 | $44.1 | +5% |
| 2023 | $44.1 | $39.7 | -10% |
| 2024 | $39.7 | $25.4 | -36% |
| 2025 | $25.4 | $26.4 | +4% |
| 2026 YTD | $26.4 | $28.5 | +8.1% |
CLDX has finished higher in four of the last six years, two of them by more than 50%. It's up 8.1% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CLDX on returns for 2026, with the stronger performance.